On July 8, 2021, Grandpharma (China) Co., Ltd. (hereinafter referred to as Grandpharma) signed a strategic cooperation agreement with Wuhan Jinyintan Hospital. Focusing on innovation, the two sides will carry out all-around cooperation in the field of drug R&D and jointly promote cutting-edge innovative research and the transformation of technological achievements. Zhang Dingyu, Member of the Party group and Deputy Director of Hubei Provincial Health Commission, the president of Wuhan Jinyintan Hospital, and the main leaders of Grandpharma attended the signing ceremony.

(Leaders and guests attending the signing ceremony)

As a designated hospital for medical treatment of public health emergencies in Wuhan, Hubei Province, Wuhan Jinyintan Hospital has accumulated rich experience in the treatment and R & D of infectious diseases, and established a national demonstrative clinical evaluation technology platform for drugs and a center for translational medicine, taking the lead in the fields of critical care medicine and antiviral and anti-infection technology in China. In the early days of the COVID-19 outbreak, Wuhan Jinyintan Hospital was the first to collect virus samples and launched a perfect national Good Clinical Practice (GCP) platform for new drugs. For these reasons, Wuhan Jinyintan Hospital played an important role in medical treatment during the most serious stage of the epidemic situation in Wuhan. Furthermore, it provided the most valuable scientific data and evidence-based support for the diagnosis and treatment of COVID-19 at home and abroad at the later stage, saving the lives of countless patients.

In the fight against COVID-19 in 2020, Grandpharma as a pharmaceutical production enterprise for epidemic prevention and control in Hubei has made all-out efforts to ensure production and supply of drugs and produced eight respiratory and cardiovascular emergency drugs included in the Huoshenshan (Fire God Mountain) Hospital and Leishenshan (Thunder God Mountain) Hospital purchase list. Furthermore, during the epidemic, the cadres and employees of the Grandpharma preparation branch, a key national production base of drugs used for emergency treatment, were not afraid of the threat of coronavirus and overcame difficulties keeping the factory producing uninterruptedly 24 hours from February 14, which fully guarantee the production and supply of drugs for epidemic prevention and control.

During the innovative R&D, Grandpharma has always attached great importance to the industry-enterprise-research institution cooperation and made active efforts in innovating the cooperative mode and exploring the long-effect mechanism of the enterprise-university-research institution cooperation, especially in the fields of critical care medicine, anti-infection and antiviral technology. Meanwhile, Grandpharma is dedicated to find out the unmet clinical needs earlier by utilizing the advantages of medical institutions, optimize the basic and clinical research, and accelerate the transformation to benefit patients as soon as possible.

This strategic cooperation is a good start. The president of Wuhan Jinyintan Hospital said that he hopes to establish a successful hospital-enterprise cooperation mode, implement feasible innovation and transformation projects, and build a benchmark for hospital-enterprise cooperation through the cooperation between Grandpharma and Wuhan Jinyintan Hospital.

In the future, Grandpharma will continue to research the innovation system of in-depth integration of the enterprises, universities, and research institutions, and build a whole innovation chain of "basic research - clinical application - translational medicine - industrial transformation", to integrate each link closely. Furthermore, Grandpharma will implement more medical innovation achievements and benefit patients.